iShares Biotechnology ETF (IBB)
| Assets | $10.64B |
| Expense Ratio | 0.44% |
| PE Ratio | 25.20 |
| Shares Out | 51.05M |
| Dividend (ttm) | $0.34 |
| Dividend Yield | 0.16% |
| Ex-Dividend Date | Sep 15, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 4.08% |
| Volume | 816,588 |
| Open | 208.43 |
| Previous Close | 209.77 |
| Day's Range | 207.78 - 211.57 |
| 52-Week Low | 140.83 |
| 52-Week High | 217.12 |
| Beta | 0.71 |
| Holdings | 248 |
| Inception Date | Feb 5, 2001 |
About IBB
Fund Home PageThe iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the NYSE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is issued by BlackRock.
Top 10 Holdings
49.96% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 8.22% |
| Vertex Pharmaceuticals Incorporated | VRTX | 7.70% |
| Amgen Inc. | AMGN | 7.68% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.51% |
| Moderna, Inc. | MRNA | 5.12% |
| Natera, Inc. | NTRA | 3.92% |
| argenx SE | ARGX | 3.76% |
| Illumina, Inc. | ILMN | 2.87% |
| Revolution Medicines, Inc. | RVMD | 2.79% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.41% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 15, 2026 | $0.01119 | Sep 18, 2026 |
| Jun 15, 2026 | $0.02377 | Jun 18, 2026 |
| Mar 17, 2026 | $0.12182 | Mar 20, 2026 |
| Dec 16, 2025 | $0.1831 | Dec 19, 2025 |
| Sep 16, 2025 | $0.08284 | Sep 19, 2025 |
| Mar 18, 2025 | $0.12117 | Mar 21, 2025 |
Performance
IBB had a total return of 49.78% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.62%.
News
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall IPO window.
Heard on the Street: With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets
With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets.
Emily Field: Large pharma companies are going to continue looking at biotech
Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.
Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide
Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge excl...
Kospi jumps 6% as Asia's battered semiconductor trade rebounds
Asian stocks rallied on Wednesday as investors returned to semiconductor shares after a bruising sell-off, taking their cue from a Wall Street rebound even as Brent crude pushed further above $91 a ba...
U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China
Western biotechs get a new playbook with tighter controls to stay ahead of China's “fast follower” pharmaceutical pipeline.
3 Healthcare ETFs to Own in a Choppy Stock Market
Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.
Market rotation is the most prevalent factor for healthcare outperformance, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss the recent performance in the healthcare sector, why sentiment has turned and much more.
BIO CEO says more consistency needed in FDA review process
U.S. biotechnology industry trade group BIO worked with the Food and Drug Administration on plans announced on Monday to speed clinical trials and expects the next initiative will aim to standardize...
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
AV Laboratories, Founded by Pioneers of IVF Solutions, to Launch Fertility Clinic Program Featuring Its Award-Winning Skincare at ESHRE 2026 in London
LONDON--(BUSINESS WIRE)---- $IBB #AVLSOM3--AV Laboratories, a science-led skincare company founded by pioneers in IVF solutions, regenerative medicine, and stem cell therapy, today announced it will e...
Biotech Investors Are Tuning Out the MAHA Chaos
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
The biotech sector took a hit this week despite a recent spike in search activity. The SPDR S&P Biotech ETF ($XBI) and iShares Biotechnology ETF ($IBB) declined slightly, while two…
Funding for Risky Biotechs Is Returning
Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.
Pharma stocks are set to take off this year, says UBS' Michael Yee
Michael Yee, global head of biotech research at UBS, joins CNBC's ‘Squawk on the Street' to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
'Fast Money' traders talk how to play biopharma space
The 'Fast Money' traders talk how to play biopharma space.
Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson
Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.
Trade Tracker: Jason Snipe buys the IBB
Jason Snipe, Founder and CIO of Odyssey Capital Advisors joins CNBC's “Halftime Report” to detail his latest purchase of the IBB.
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.